These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18030307)

  • 61. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.
    Spreafico M; Lodigiani C; van Leeuwen Y; Pizzotti D; Rota LL; Rosendaal F; Mannucci PM; Peyvandi F
    Pharmacogenomics; 2008 Sep; 9(9):1237-50. PubMed ID: 18781852
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
    Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
    Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
    Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose.
    Suarez-Kurtz G; Perini JA; Silva-Assunção E; Struchiner CJ
    Blood; 2009 Apr; 113(17):4125-6. PubMed ID: 19389892
    [No Abstract]   [Full Text] [Related]  

  • 68. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
    Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.
    Kato Y; Ichida F; Saito K; Watanabe K; Hirono K; Miyawaki T; Yoshimura N; Horiuchi I; Taguchi M; Hashimoto Y
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):295-9. PubMed ID: 21273734
    [TBL] [Abstract][Full Text] [Related]  

  • 70. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
    Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
    Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
    Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
    Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
    Ames PR; Margaglione M; Ciampa A; Colaizzo D; Ferrara F; Iannaccone L; Vincenzobrancaccio
    Thromb Res; 2011 Jun; 127(6):595-9. PubMed ID: 21371740
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Validation of warfarin pharmacogenetic algorithms in clinical practice.
    Marin-Leblanc M; Perreault S; Bahroun I; Lapointe M; Mongrain I; Provost S; Turgeon J; Talajic M; Brugada R; Phillips M; Tardif JC; Dubé MP
    Pharmacogenomics; 2012 Jan; 13(1):21-9. PubMed ID: 22176621
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype.
    Osman A; Enström C; Lindahl TL
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):293-6. PubMed ID: 17413769
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Warfarin resistance.
    Sinxadi P; Blockman M
    Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
    [TBL] [Abstract][Full Text] [Related]  

  • 79. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
    Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
    Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
    Moon HW; Noh J; Yun YM; Kim HY; Yun IJ; Song J; Kim JQ
    Ann Clin Lab Sci; 2011; 41(3):229-35. PubMed ID: 22075505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.